Fluoguide AS
STO:FLUO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fluoguide AS
Selling, General & Administrative
Fluoguide AS
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Selling, General & Administrative
-kr21m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Selling, General & Administrative
-kr619m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-47%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Selling, General & Administrative
-kr489.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-30%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Selling, General & Administrative
-$10.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Selling, General & Administrative
-€448m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-47%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Selling, General & Administrative
-kr1.2B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-19%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Selling, General & Administrative?
Selling, General & Administrative
-21m
DKK
Based on the financial report for Dec 31, 2025, Fluoguide AS's Selling, General & Administrative amounts to -21m DKK.
What is Fluoguide AS's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-35%
Over the last year, the Selling, General & Administrative growth was 0%. The average annual Selling, General & Administrative growth rates for Fluoguide AS have been -13% over the past three years , -35% over the past five years .
